Biomarker-Based Precision Therapy for Alzheimer's Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine.

J Clin Med · 2024 · PMC11355840 · PMID 39200803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Neflamapimod (target class: inflammation), a p38α kinase inhibitor, demonstrated a favorable trend for NRGN and decreased CSF levels of pTau181 and tTau in comparison to a placebo.

also in 714 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.